Red Rock Resorts 株価情報 (NASDAQ: RRR)

最新ニュース Red Rock Resorts (NASDAQ:RRR) 株価情報

Red Rock Resorts

Red Rock Resorts Inc along with its subsidiary is a gaming, development, and management company. The company mainly develops strategically located casino and entertainment properties. It generates a majority of its revenue from Casino.

Red Rock Resorts, Inc. - Class A Common Stock

Red Rock Resorts Inc

ROCK RIDGE RESOURCES INC by Rock Ridge Resources, Inc.

Rock Ridge Resources Inc

ROCKRIDGE RESOURCES LTD by Rockridge Resources Ltd.

R-THREE TECHNOLOGIES INC by R-Three Technologies, Inc.

R-Three Technologies Inc

R&R Real Estate Investment Trust

<a href="https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines" title="https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines">https://www.wsj.com/health/healthcare/white-house-preparing-order-to-cut-thousands-of-federal-health-workers-bd1e0b7f?mod=latest_headlines</a>

Health Care

Politics

General

WSJ: "White House Preparing Order to Cut Thousands of Federal Health Workers"

Thursday,&nbsp;Laboratory Corp&nbsp;(NYSE: LH) reported fourth-quarter 2024 adjusted earnings per share of $3.45, up from $3.30 a year ago, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.39</a>.
Sales increased 9.8% year-over-year to $3.33 billion, almost in line with the consensus of $3.31 billion.
The increase was due to organic revenue growth of 5.4%, acquisitions, net of divestitures of 4%, and foreign&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43523377/labcorp-announces-2024-fourth-quarter-and-full-year-results" rel="noreferrer noopener">currency translation of 0.3%</a>.
&#8220;In 2024, Labcorp delivered exceptional results driven by both organic and inorganic growth,&#8221; said&nbsp;Adam Schechter, chairman and CEO of Labcorp&#8230;Additionally, we strengthened our presence in key high growth areas including oncology, women&#8217;s health, neurology and autoimmune disease. In 2025, we are positioned to deliver strong growth and margin expansion across both Diagnostics Laboratories and Biopharma Laboratory Services&#8230;&#8221;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
Adjusted operating income for the quarter was&nbsp;$423.2&nbsp;million, or 12.7% of revenue, compared to&nbsp;$394.9 million, or 13%, in the fourth quarter.
William Blair analyst Andrew F. Brackmann writes, &#8220;We continue to believe the underlying business at Labcorp is on solid footing, as the diagnostics segment benefits from favorable macro tailwinds and the BLS segment sees solid growth in central labs (albeit decelerating off tough comps) and early development returns to growth.&#8221;
This positions the stock well for 2025, with stable guidance and potential for gains if the company&#8217;s momentum continues.
William Blair reiterates the Outperform rating.
Guidance: LabCorp expects 2025 adjusted EPS of 15.60-$16.40 versus the consensus of $16.0. It expects 2025 sales of $13.9 billion-$14.1 billion versus consensus Of $13.8 billion.
The guidance includes 2025 Diagnostics Laboratories sales growth of 6.5%- 7.7% and Biopharma Laboratory Services&nbsp;sales growth of 3.0%- 5.0%.
Price Action:&nbsp;Laboratory stock is down 0.92% at $247.68 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43523277/volkswagen-unveils-plan-for-e20000-entry-level-electric-car" target="_blank" rel="noreferrer noopener">Volkswagen Unveils Plan For Entry-Level, $20K ID Electric Car: Details</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Analyst Color

Earnings

News

Guidance

Analyst Ratings

Trading Ideas

Laboratory Corporation Of America Holdings

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Macro Economic Events

Global

Economics

US Treasury Secretary Bessent Says I See China Eating Some Tariffs No Matter The Level

White House Press Secretary Says More Than 40,000 Federal Employees Have Accepted Buyouts

Agilent Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) short percent of float has risen 13.04% since its last report. The company recently reported that it has 3.29 million shares sold short, which is 1.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.16 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Agilent Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865723_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agilent Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Agilent Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Agilent Technologies's peer group average for short interest as a percentage of float is 5.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Agilent Technologies's Recent Short Interest

McDonald's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) short percent of float has risen 3.05% since its last report. The company recently reported that it has 9.67 million shares sold short, which is 1.35% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>McDonald's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for McDonald's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing McDonald's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, McDonald's's peer group average for short interest as a percentage of float is 9.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About McDonald's?

Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) short percent of float has risen 4.41% since its last report. The company recently reported that it has 17.20 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Johnson &amp; Johnson Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738865712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Johnson &amp; Johnson has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Johnson &amp; Johnson's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Johnson &amp; Johnson's peer group average for short interest as a percentage of float is 4.13%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(JNJ) - Analyzing Johnson & Johnson's Short Interest

A federal judge on Thursday restricted the handling of sensitive Department of Treasury data amid concerns over access granted to allies of Elon Musk leading <a href="https://www.benzinga.com/topic/elon-musk">a government review.</a>
The decision follows a lawsuit filed by labor unions arguing that the Department of Government Efficiency (DOGE) led by Musk appointees could compromise financial records, The Wall Street Journal <a href="https://www.wsj.com/politics/policy/judge-approves-limits-on-sharing-treasury-data-after-musk-allies-move-in-e0a86ec0?mod=hp_lead_pos10">reports</a>.
What Happened: The ruling, issued by U.S. District Judge Colleen Kollar-Kotelly in Washington, allows two Musk associates, Tom Krause and Marko Elez, to retain access to a Treasury payment system processing financial data of millions of Americans. However, they are now limited to &#8220;read-only&#8221; privileges and are prohibited from sharing information externally, according to WSJ.
This follows a lawsuit filed Monday by AFL-CIO and other labor organizations, represented by Public Citizen, seeking to block DOGE's access to the Bureau of the Fiscal Service, citing risks of exposing social security numbers and banking details. The court's order is temporary while Kollar-Kotelly considers a broader injunction.
Also Read: <a href="https://www.benzinga.com/25/02/43534797/tesla-sales-drop-60-in-germany-are-elon-musks-politics-getting-in-the-way-of-ev-growth">Tesla Sales Drop 60% In Germany: Are Elon Musk&#8217;s Politics Getting In The Way Of EV Growth?</a>
DOGE, created under President Donald Trump's administration, was initially an advisory body but was formally integrated into the president&#8217;s Executive Office through a day-one executive order.
Musk's team has sought federal databases and spending records, drawing scrutiny from government officials and watchdog groups. The Department of Treasury confirmed Krause and Elez were given special employment status and access to financial records, though the Justice Department argued in court that neither had shared data with outside parties, including Musk, WSJ reports.
Why It Matters: The lawsuit signals growing resistance to DOGE's actions as it gains access to government agencies. According to a Wednesday report, DOGE representatives were granted access to Centers for Medicare and Medicaid Services (CMS) payment systems. Musk said on X that fraud within CMS represented &#8220;big money fraud,&#8221; aligning with DOGE's mission to <a href="https://www.benzinga.com/25/02/43516681/doge-gains-access-to-medicare-and-medicaid-systems-elon-musk-says-this-is-where-the-big-money-fraud-is-happening">cut government spending.</a>
The ruling raises concerns about transparency, as Musk's appointees push forward with their mandate to cut $1 trillion from federal expenditures. Labor unions argue that DOGE's expanding influence threatens the privacy of millions who rely on federal programs. 
While the judge's order limits immediate risks, the broader battle over DOGE's authority is ongoing.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43529306/tariffs-are-a-means-to-an-end-bessent-defends-trade-strategy-pushes-growth-plan">&#8216;Tariffs Are A Means To An End&#8217;: Bessent Defends Trade Strategy, Pushes Growth Plan</a></li>
</ul>
Photo: Shutterstock
<hr class="wp-block-separator has-alpha-channel-opacity" />

Government

Legal

Musk Allies Face Treasury Data Limits As Judge Steps In

Several analysts raised the price target on Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) following fourth-quarter 2024 <a target="_blank" href="https://www.benzinga.com/quote/fi/analyst-ratings" rel="noreferrer noopener">results reported on Wednesday.</a>
The company reported revenue of $5.25 billion, beating the&nbsp;analyst consensus estimate of $4.96 billion, and adjusted EPS of $2.51, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43501055/fiserv-q4-earnings-merchant-financial-solutions-fuel-growth-double-digit-outlook-for-2025" rel="noreferrer noopener">analyst consensus estimate of $2.48</a>.&nbsp;
Fiserv&nbsp;expects FY25&nbsp;organic revenue&nbsp;growth of 10%-12% and adjusted EPS outlook of $10.10-$10.30, representing&nbsp;growth of 15%-17% Y/Y vs. the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$10.20 consensus</a>.
Stephens analyst Charles Nabhan raised the price forecast from $255 to $270 while reaffirming an Overweight rating.
The analyst writes that the lapping of Argentina comparables and the timing of go-lives should lead to first-quarter organic growth of less than 10% and second-half growth of above 12%.
With the transitory impact of excess inflation and Dolar Turista weakening through the year, the analyst expects adjusted and organic revenue to converge through the year.
For 2025, Nabhan projects a 1.5% foreign exchange headwind and estimates FY26 adj. EPS of $12.06.
Also, Keefe, Bruyette &amp; Woods analyst Vasundhara Govil raised the price forecast from $238 to $260 while reaffirming an Outperform rating.
The analyst says that Fiserv continues to experience healthy business trends, with volume growth in line with Visa and Mastercard across SMB and Enterprise segments and momentum carrying into January.
Distribution expansion and new product rollouts are strengthening Clover, while upcoming new client wins in 2025 should drive further growth in Financial Solutions, per the analyst.
The analyst increased the FY25 EPS estimate to $10.20 (from $10.10) and FY26 EPS estimate to $11.75 (from $11.65) to reflect the quarterly beat and strong underlying growth drivers.
Moreover, KeyBanc analyst Alex Markgraff raised the price forecast from $250 to $270 while maintaining an Overweight rating.
The analyst says that Fiserv&#8217;s results were solid, with strong Clover revenue growth and above-Street FY25 guidance for adjusted revenue and EPS standing out as key positives.
Management&#8217;s commentary on the CEO transition and FY25 growth opportunities was encouraging, despite some uneven growth cadence, adds the analyst.
As a result, Markgraff raised the FY25/FY26 estimates, driven primarily by stronger Merchant Solutions growth and margin expansion.
Additionally, RBC Capital Markets analyst Daniel R. Perlin raised the price forecast from $255 to $270 while maintaining an Outperform rating.
The analyst says that FI delivered strong results, exceeding expectations, with Clover revenue up 29% year-over-year and issuing FY25 guidance that supports continued momentum.
The analyst adjusted FY25 revenue estimate to $20.5 billion (from $20.8 billion) while maintaining the adjusted EPS estimate at $10.20. Additionally, Perlin estimates FY26 of $22.2 billion in revenue and $11.80 in adjusted EPS.
Investors can gain exposure to the stock via TCW Compounders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRW#NYSE">GRW</a>) and Global X FinTech ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FINX#NASDAQ">FINX</a>).
Price Action: FI shares are up 0.48% at $230.64 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43507132/stocks-rebound-google-eyes-worst-drop-in-a-year-gold-shatters-fresh-records-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo via Shutterstock.

Equities

Large Cap

Price Target

Reiteration

FINX

Fiserv Fires On All Cylinders, Analysts Bump Up Price Forecasts Post Q4 Results

On Thursday,&nbsp;Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>)&nbsp;reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the Street estimates of $2.30.</a>
The orthopedic giant reported sales of $2.02 billion, up 4.3% on a reported basis (+4.9% on constant currency), beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43522914/zimmer-biomet-announces-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $2.014 billion</a>.
Knee product sales increased 5.1% to $839.2 million, and hip product sales increased 3% (+4% on constant currency) to $520 million.
Sports Medicine products generated sales of $489.4 million, up 8% (+8.4%).
"We have committed to diversifying our portfolio outside of core orthopedics and investing in attractive, higher-growth segments. Our recently announced agreement to acquire Paragon 28 marks a bold step towards executing on our diversification ambitions; once the transaction is closed, we expect our S.E.T. business to be larger than our Hip business, and to grow at a much faster pace," said Ivan Tornos, Zimmer Biomet's President and CEO.
Operating margin improved to 19.2% from 18.3%.
Recently, Zimmer Biomet agreed to acquire Paragon 28, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NASDAQ">FNA</a>) for an upfront cash payment of&nbsp;$13.00&nbsp;per share, corresponding to an equity value of approximately&nbsp;$1.1 billion&nbsp;and an enterprise value of <a target="_blank" href="https://www.benzinga.com/news/guidance/25/01/43297796/zimmer-biomet-snaps-up-paragon-28-in-1-2-billion-deal-details" rel="noreferrer noopener">approximately&nbsp;$1.2 billion</a>.
Paragon 28 shareholders will also receive a contingent value right, which entitles the holder to up to&nbsp;$1.00&nbsp;per share in cash if certain revenue milestones are achieved.
Guidance: Zimmer Biomet expects fiscal year 2025 adjusted EPS of $8.15-$8.35 versus consensus of $8.55. The company expects 2025 revenue growth of 1%-3.5%.
Price Action:&nbsp;ZBH stock is down 3.13% at $104.86 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43527514/astrazeneca-q4-earnings-revenue-and-eps-beat-on-higher-cancer-and-respiratory-drug-sales-faces-4-5-million-potential-fine-in-china" target="_blank" rel="noreferrer noopener">AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China</a></li>
</ul>

Movers

Why Is Zimmer Biomet Stock Trading Lower On Thursday?

Mizuho analyst John Baumgartner maintains BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) with a Outperform and raises the price target from $80 to $85.

BRBR

Mizuho Maintains Outperform on BellRing Brands, Raises Price Target to $85

WIIM

Maximus shares are trading lower after the company reported Q1 financial results and cut its FY25 revenue guidance below estimates.

JP Morgan analyst Bill Peterson reiterated an Overweight rating on the shares of Enovix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) with a <a href="https://www.benzinga.com/quote/ENVX/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $15.00.</a>
Enovix will release financial results for the&nbsp;fourth quarter&nbsp;<a target="_blank" href="https://www.benzinga.com//node/43323466" rel="noreferrer noopener">on February 19, 2025.</a>
The analyst anticipates fourth-quarter results to meet expectations, along with positive commentary regarding customer discussions, order pipeline, and positioning in light of tariffs and geopolitical factors.
Additionally, an update on the ongoing CFO search is expected. The analyst&#8217;s forecast predicts an adjusted EBITDA loss of -$19.8 million (compared to the Street estimate of -$22.9 million and the guidance of -$19 million to -$25 million).
The stock is likely to respond favorably to announcements regarding the progress of EX-2M product development, optimization of Fab-2 in preparation for mass production in 2026, and advancements in product qualification.
The analyst recalled that management has stated if Enovix can deliver battery samples to its first customers by second-quarter 2025, they may secure an order by third-quarter 2025 for a fourth-quarter 2025 ramp in smartphone production.
The analyst also expects management to address tariff impacts, reinforcing that Enovix is well-positioned as a non-Chinese battery supplier with a diversified supply chain.
Despite the elevated short interest, it has receded from previous highs, and the analyst remains confident in Enovix&#8217;s ability to execute its plans.
This confidence is driven by strong management, transparency, and a robust demand pipeline, although the analyst recognizes the competitive risks, especially with smartphone customer qualifications not expected until well into 2025.
Enovix is strategically positioned to secure design wins and achieve substantial revenue growth in the years ahead, leveraging the performance and safety benefits of its products, said the analyst.
Although potential risks include challenges in ramping up production to meet demand and limited expansion into the EV battery market, the analyst notes Enovix is well-equipped to capture significant market share and navigate these challenges successfully.
Price Action: ENVX shares are trading higher by 4.32% at $12.07 at the last check Thursday.
Photo: Piotr Swat via Shutterstock.

ENVX

Enovix Set To Meet Q4 Expectations, Eyes Smartphone Battery Breakthrough: JP Morgan

Goldman Sachs analyst Christine Cho maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Sell and lowers the price target from $17 to $15.

Goldman Sachs Maintains Sell on Wendy's, Lowers Price Target to $15

Goldman Sachs analyst Thiago Ojea maintains Ternium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TX#NYSE">TX</a>) with a Buy and lowers the price target from $45 to $39.

Goldman Sachs Maintains Buy on Ternium, Lowers Price Target to $39

Goldman Sachs analyst Mark Delaney maintains Symbotic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) with a Neutral and lowers the price target from $28 to $25.

Goldman Sachs Maintains Neutral on Symbotic, Lowers Price Target to $25

Goldman Sachs analyst Tito Labarta maintains StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) with a Buy and lowers the price target from $16 to $14.

STNE

Goldman Sachs Maintains Buy on StoneCo, Lowers Price Target to $14

Goldman Sachs analyst Eric Sheridan maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $550 to $695.

SPOT

Goldman Sachs Maintains Buy on Spotify Technology, Raises Price Target to $695

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) with a Buy and maintains $20 price target.

RNAZ

HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target

Goldman Sachs analyst Toshiya Hari maintains Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) with a Neutral and lowers the price target from $92 to $70.

SWKS

Goldman Sachs Maintains Neutral on Skyworks Solutions, Lowers Price Target to $70

Nevada casinos see a drop in gaming win for the fifth month in a row

Morgan Stanley analyst Stephen Grambling lowered the firm's price target on Red Rock Resorts (RRR) to $48 from $52 and keeps an Overweight rating o...

Red Rock Resorts price target lowered to $48 from $52 at Morgan Stanley

JMP Securities lowered the firm's price target on Red Rock Resorts (RRR) to $57 from $61 and keeps an Outperform rating on the shares. Maryland rel...

Red Rock Resorts price target lowered to $57 from $61 at JMP Securities

Baron Focused Growth Fund Q4 2024 Shareholder Letter

In a report released today, Daniel Politzer from Wells Fargo maintained a Hold rating on Red Rock Resorts (RRR – Research Report), with a price tar...

Wells Fargo Sticks to Their Hold Rating for Red Rock Resorts (RRR)

In a report released today, Brandt Montour from Barclays maintained a Buy rating on Red Rock Resorts (RRR – Research Report), with a price target o...

Barclays Reaffirms Their Buy Rating on Red Rock Resorts (RRR)

Barclays analyst Brandt Montour lowered the firm's price target on Red Rock Resorts (RRR) to $58 from $62 and keeps an Overweight rating on the sha...

Red Rock Resorts price target lowered to $58 from $62 at Barclays

Baron Small Cap Fund Q4 2024 Shareholder Letter

Nevada casinos returned to growth in December as slots action offset weakness with sportsbooks, baccarat, and craps

Baron Small Cap Fund: Q4 2024 Top Contributors And Detractors

ABNB

ACGL

ALTR

ANSS

ASGN

AZPN

BALY

BCAP

BFAM

BIRK

BROE

BWIN

CAKE

CGNX

COLD

CSGP

CWAN

DAVA

DNUT

DRVN

DXCM

EWCZ

EXPO

FIGS

FOXF

FROG

GDYN

GTLS

GWRE

HLLY

IBKR

ICLR

ICON

IDXX

ILMN

INDI

INTA

IRDM

KNSL

KTOS

LLYVA

LLYVB

LLYVK

MSCI

NEOG

ONON

PLNT

SHOP

SITE

TREX

TSLA

VRSK

WYNN

Press Releases

Red Rock Resorts Announces First Quarter 2024 Conference Call and Earnings Release Date

Red Rock Resorts Announces First Quarter 2024 Results

Red Rock Resorts Announces Second Quarter 2024 Conference Call and Earnings Release Date

Red Rock Resorts Announces Revised Date of Second Quarter 2024 Conference Call and Earnings Release Date

Red Rock Resorts Announces Second Quarter 2024 Results

Red Rock Resorts Announces Date of Third Quarter 2024 Conference Call and Earnings Release Date

Red Rock Resorts Announces Revised Date of Third Quarter 2024 Conference Call and Earnings Release Date

Red Rock Resorts Announces Third Quarter 2024 Results

31st Annual Baron Investment Conference Draws Over 5,000 Shareholders and Clients

Red Rock Resorts Announces Date of Fourth Quarter and Full Year 2024 Conference Call and Earnings Release Date

Accel Entertainment

PlayAGS

Ballys

Boyd Gaming

Codere Online Luxembourg, S.A. - Ordinary Shares

Codere Online Luxembourg

Churchill Downs, Incorporated - Common Stock

Churchill Downs

Canterbury Park Holding Corporation - Common Stock

Canterbury Park Holding

Caesars Entertainment, Inc. - Common Stock

Caesars Entertainment

DraftKings

Everi Hldgs

Full House Resorts

Golden Entertainment, Inc. - Common Stock

Golden Entertainment

Genius Sports

International Game Technology Ordinary Shares

Intl Game Tech

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment

Light & Wonder

Las Vegas Sands

Monarch Casino & Resort, Inc. - Common Stock

Monarch Casino & Resort

MGM Resorts Intl

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Enter

Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares

Comments

Red Rock Resorts

ニュース

最新ニュース Red Rock Resorts (NASDAQ:RRR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル